We sought to discover promising drug targets for Alzheimer's disease (AD) by combining high-throughput proteomics in brain and blood with genetic data to determine the genomic architecture associated protein levels in AD.
No takes yet. Share an insight, caveat, or question.
Ou et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: